<?xml version="1.0" encoding="UTF-8"?>
<ref id="B175-pharmaceutics-12-00171">
 <label>175.</label>
 <element-citation publication-type="journal">
  <person-group person-group-type="author">
   <name>
    <surname>Grande</surname>
    <given-names>F.</given-names>
   </name>
   <name>
    <surname>Ioele</surname>
    <given-names>G.</given-names>
   </name>
   <name>
    <surname>Occhiuzzi</surname>
    <given-names>M.A.</given-names>
   </name>
   <name>
    <surname>De Luca</surname>
    <given-names>M.</given-names>
   </name>
   <name>
    <surname>Mazzotta</surname>
    <given-names>E.</given-names>
   </name>
   <name>
    <surname>Ragno</surname>
    <given-names>G.</given-names>
   </name>
   <name>
    <surname>Garofalo</surname>
    <given-names>A.</given-names>
   </name>
   <name>
    <surname>Muzzalupo</surname>
    <given-names>R.</given-names>
   </name>
  </person-group>
  <article-title>Reverse Transcriptase Inhibitors Nanosystems Designed for Drug Stability and Controlled Delivery</article-title>
  <source>Pharmaceutics</source>
  <year>2019</year>
  <volume>11</volume>
  <elocation-id>197</elocation-id>
  <pub-id pub-id-type="doi">10.3390/pharmaceutics11050197</pub-id>
 </element-citation>
</ref>
